JP2017502003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502003A5 JP2017502003A5 JP2016538037A JP2016538037A JP2017502003A5 JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5 JP 2016538037 A JP2016538037 A JP 2016538037A JP 2016538037 A JP2016538037 A JP 2016538037A JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5
- Authority
- JP
- Japan
- Prior art keywords
- phe
- pro
- tyr
- aib
- nal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical group OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915662P | 2013-12-13 | 2013-12-13 | |
| US61/915,662 | 2013-12-13 | ||
| PCT/EP2014/077240 WO2015086686A2 (en) | 2013-12-13 | 2014-12-10 | Protease resistant peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502003A JP2017502003A (ja) | 2017-01-19 |
| JP2017502003A5 true JP2017502003A5 (enExample) | 2017-12-28 |
Family
ID=52021207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538037A Pending JP2017502003A (ja) | 2013-12-13 | 2014-12-10 | プロテアーゼ耐性ペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160318987A1 (enExample) |
| EP (2) | EP3415526A1 (enExample) |
| JP (1) | JP2017502003A (enExample) |
| KR (1) | KR20160098406A (enExample) |
| CN (1) | CN105849123A (enExample) |
| AU (1) | AU2014363547A1 (enExample) |
| BR (1) | BR112016013157A2 (enExample) |
| CA (1) | CA2933405A1 (enExample) |
| MX (1) | MX2016007407A (enExample) |
| SG (1) | SG10201805039UA (enExample) |
| WO (1) | WO2015086686A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726889B (zh) | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| CA3003465A1 (en) | 2015-10-28 | 2017-05-04 | Krishna Kumar | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
| CA3025592A1 (en) | 2016-06-09 | 2017-12-14 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| PE20211417A1 (es) | 2018-04-05 | 2021-08-02 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1 |
| CN115348876A (zh) * | 2020-03-31 | 2022-11-15 | 安塔罗斯医疗公司 | 用于成像和治疗目的的包含螯合部分的选择性gip受体激动剂 |
| CN116685599A (zh) * | 2020-12-16 | 2023-09-01 | 免疫医疗有限公司 | 多肽及其用途 |
| TW202346323A (zh) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的glp—1及升糖素雙重激動肽 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG125915A1 (en) * | 1998-12-07 | 2006-10-30 | Sod Conseils Rech Applic | Analogues of glp-1 |
| PT1987052E (pt) * | 2006-02-08 | 2011-07-25 | Lonza Ag | Síntese de péptidos tipo glucagina |
| EP2021014A1 (en) * | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| WO2008023050A1 (en) * | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| CA2707448C (en) * | 2007-12-11 | 2014-10-14 | Cadila Healthcare Limited | Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities |
| EP2110380B1 (en) * | 2008-04-18 | 2010-11-10 | F. Hoffmann-La Roche AG | Alpha-N-methylation of amino acids |
| WO2011048614A2 (en) * | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
| US20130143800A1 (en) * | 2011-11-07 | 2013-06-06 | Research Development Foundation | Combination therapies to treat diabetes |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| WO2014088631A1 (en) * | 2012-12-06 | 2014-06-12 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
-
2014
- 2014-12-10 SG SG10201805039UA patent/SG10201805039UA/en unknown
- 2014-12-10 EP EP18182275.0A patent/EP3415526A1/en not_active Withdrawn
- 2014-12-10 EP EP14809857.7A patent/EP3080153A2/en not_active Withdrawn
- 2014-12-10 KR KR1020167018887A patent/KR20160098406A/ko not_active Withdrawn
- 2014-12-10 BR BR112016013157A patent/BR112016013157A2/pt not_active Application Discontinuation
- 2014-12-10 CA CA2933405A patent/CA2933405A1/en not_active Abandoned
- 2014-12-10 AU AU2014363547A patent/AU2014363547A1/en not_active Abandoned
- 2014-12-10 WO PCT/EP2014/077240 patent/WO2015086686A2/en not_active Ceased
- 2014-12-10 US US15/103,607 patent/US20160318987A1/en not_active Abandoned
- 2014-12-10 MX MX2016007407A patent/MX2016007407A/es unknown
- 2014-12-10 CN CN201480067307.1A patent/CN105849123A/zh active Pending
- 2014-12-10 JP JP2016538037A patent/JP2017502003A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502003A5 (enExample) | ||
| AR096162A1 (es) | Péptidos terapéuticos | |
| TWI455721B (zh) | 癌疫苗組合物 | |
| NZ600732A (en) | Oxyntomodulin peptide analogue | |
| EP3412304A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| MX2019001925A (es) | Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo. | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| WO2015188132A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| JP2017535527A5 (enExample) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| WO2012027379A3 (en) | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines | |
| RU2011134596A (ru) | Аналоги оксинтомодулина | |
| JP2017522362A5 (enExample) | ||
| NZ708990A (en) | Method for activating helper t cell | |
| MX2024006356A (es) | Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| AR096927A1 (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 | |
| MX2014008028A (es) | Proteina de fusion anticancerigena. | |
| JP2019525753A5 (enExample) | ||
| CO2019013768A2 (es) | Compuestos de mic-1 y usos de estos | |
| SA521421371B1 (ar) | لقاحات الببتيد | |
| WO2012174397A3 (en) | Anti-inflammatory pharmaceutical products | |
| MX337756B (es) | Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo. |